BACKGROUND AND PURPOSE Zileuton is the only 5‐lipoxygenase (5‐LOX) inhibitor marketed as a treatment for asthma, and is often utilized as a selective tool to evaluate the role of 5‐LOX and leukotrienes. The aim of this study was to investigate the effect of zileuton on prostaglandin (PG) production in vitro and in vivo.

Zileuton effectively suppresses prostaglandin biosynthesis by inhibiting arachidonic acid release in macrophages, potentially benefiting asthma patients.

Paper

The 5‐lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages

References

Citations